Drugs / CANOCTAKIN
CANOCTAKIN
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT01627002 | May 2012 → Apr 2013 | — | ProtAffin Biotechnologie AG | Terminated | No outcome recorded |
Evidence & citations 8 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | CANOCTAKIN | ChEMBL registry synonym — accepted as the source's own label CHEMBL4298068 ↗ |
| Known as | Canoctakina | ChEMBL registry synonym — accepted as the source's own label CHEMBL4298068 ↗ |
| Known as | Canoctakine | ChEMBL registry synonym — accepted as the source's own label CHEMBL4298068 ↗ |
| Known as | Glycafilin | ChEMBL registry synonym — accepted as the source's own label CHEMBL4298068 ↗ |
| Known as | PA401 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01627002 ↗ |
| Action | Inhibit | “PA401 is a potent inhibitor of neutrophil activation and transmigration” NCT01627002 ↗ |
| Modality | Protein / enzyme biologic | “PA401 is a genetically engineered and recombinantly expressed mutant of the bioactive form of human interleukin-8.” NCT01627002 ↗ |
| Route | Subcutaneous | “Part A of Study: Subcutaneous, 0.1mg to 50mg, single ascending doses” NCT01627002 ↗ |